The addition of cisplatin or cetuximab to radiation therapy (RT) improves outcomes in comparison with RT alone in the nonoperative management of head and neck squamous cell carcinoma (HNSCC), but limited data exist for comparing these approaches. Using Veterans Health Affairs data, this study compared the outcomes of patients treated with RT plus cisplatin or cetuximab. METHODS: Patients with stage III to IVb HNSCC who had been treated nonsurgically with RT and cisplatin or cetuximab from 2000 to 2016 within the Veterans Health Affairs system were identified. Patients were analyzed by the drug used in the first treatment cycle (intent to treat). Overall survival (OS) was compared by treatment group with Cox regression models, and propensity score (PS) methods were used to account for a treatment allocation bias. The risk of toxicities was determined, with logistic regression models fit into propensity-matched cohorts. RESULTS: A total of 4520 patients were included in the analysis with a median follow-up of 3 years: 83% received cisplatin. Cisplatin patients were younger (P < .001) and had fewer comorbidities (P < .001). In an unmatched analysis, cetuximab was associated with inferior OS (P < .001). After PS matching, cetuximab treatment remained statistically significantly associated with inferior OS (1.7 vs 4.1 years; hazard ratio, 1.61; 95% confidence interval, 1.44-1.79; P < .001). These differences remained significant across all primary HNSCC subsites and in comparison with low-and high-dose cisplatin. CONCLUSIONS: Cetuximab with RT yields inferior OS in comparison with cisplatin for the nonoperative management of stage III to IVb HNSCC. According to this study, cisplatin may be the most appropriate partner for RT in this setting. Cancer 2019;125:406-415.
INTRODUCTION
Head and neck squamous cell carcinoma (HNSCC) is a relatively common cancer, with nearly 50,000 new cases estimated in the United States in 2017. 1 Most patients present with locally advanced disease, which is treated with a combination of surgery, radiation therapy (RT), and systemic therapy. For patients opting for nonoperative management, the standard of care is definitive RT with concurrent systemic therapy. There are currently 2 systemic treatments with phase 3 data supporting their use: cisplatin 2 and cetuximab. 3, 4 Each of these agents has been shown to lead to improved overall survival (OS) in comparison with RT alone. Guidelines view either option as a reasonable approach, 5 and perhaps because of the impression that the toxicity profile is superior for cetuximab, 2,3,6-11 many physicians opt for its use. There are scant prospective data comparing the relative efficacy of cisplatin and cetuximab in HNSCC, and it is unclear whether cetuximab is actually less toxic. One published trial aimed to compare these 2 drugs when they were given with RT, but it was significantly underpowered because of slow accrual: only 70 patients were randomized. In that analysis, serious adverse events were, in fact, more common with cetuximab. 12 Multiple retrospective analyses have compared outcomes for platinum and cetuximab in this setting. Although some showed cetuximab to be inferior to platinum-sensitized RT, [13] [14] [15] 1 series showed similar outcomes. 16 All of these were limited by a relatively small sample size, so they could not
Cancer February 1, 2019 perform robust subgroup analyses or control effectively for confounding by indication. The Radiation Therapy Oncology Group (RTOG) and Trans-Tasman Radiation Oncology Group cooperative groups are currently performing phase 3 studies comparing these agents among patients with p16(+) (human papillomavirus [HPV]-related) oropharyngeal cancers. A press release recently reported that cetuximab was inferior to cisplatin in the RTOG 1016 trial. Nevertheless, no randomized clinical trials are currently ongoing to address the relative efficacy of cisplatin versus cetuximab among patients with p16(-) tumors. This is particularly relevant because some data for patients with metastatic HNSCC indicate that epidermal growth factor receptor inhibition may have more pronounced importance in p16(-) tumors. 17 An analysis of cancer registry data linked to clinical information may be a practical way to inform clinical practice for this issue.
We have previously used clinical data from the Veterans Affairs (VA) Corporate Data Warehouse (CDW) to evaluate the effect of cisplatin dosing on clinical outcomes in HNSCC. 18 The CDW contains registry-based cancer data linked to detailed clinical information for patients treated at VA medical centers across the United States. In contrast to claims data or other cancer registries, the CDW includes pharmacy data describing chemotherapy dosing and frequency as well as detailed comorbidity, behavioral, and laboratory data, and it thereby provides detailed real-world comparative effectiveness data on cetuximab versus cisplatin with RT for locally advanced HNSCC.
MATERIALS AND METHODS

Patient Selection
Using the CDW, we identified patients with unresected stage III to IVb HNSCC (American Joint Committee on Cancer, 7th edition) treated with RT and either cisplatin or cetuximab from 2000 to 2016 within the VA health system. To be consistent with prior landmark trials in HNSCC, 2,10,11 we evaluated patients with squamous cell carcinoma of the oral cavity, oropharynx, and hypopharynx/larynx. We excluded patients with nasopharyngeal, sinus, and other less common tumors. We also excluded patients who underwent definitive surgery before RT, but we did allow patients who underwent diagnostic procedures such as lymph node biopsy (Fig. 1). 
Study Variables
VA databases were used to identify baseline sociodemographic variables. Comorbid illnesses present in outpatient and inpatient VA claims databases were identified Cancer February 1, 2019 with diagnostic codes in the 12 months before the cancer diagnosis. Specific comorbidities relevant to treatment decision making regarding the systemic therapy choice were also identified (eg, hearing loss and neuropathy), and we then calculated Charlson-Deyo scores for each subject to estimate the overall burden of comorbidities. [19] [20] [21] Marital status and alcohol use data were collected from VA oncology files, and the smoking status was classified with VA Health Factors data and augmented with registry data. 22 Baseline creatinine values and estimated glomerular filtration rate estimates were ascertained from VA laboratory data. Cancer data, including the diagnosis date, cancer stage, histologic subtype, and anatomic site, were collected from VA oncology files. The initial course of cancer treatment was determined with published methods for combined registry and administrative data; we supplemented oncology registry data by using procedure codes to identify definitive surgical procedures and radiotherapy use. 23 We used the intravenous medication pharmacy files to ascertain systemic therapy use and dose. Given the differential dosing practices surrounding cisplatin, we identified patients as receiving high-dose cisplatin (HDC; 80-120 mg/m 2 ) or low-dose cisplatin (LDC; 30-50 mg/m 2 ). Patients were analyzed in an intent-to-treat fashion on the basis of the first regimen administered; for example, patients who began receiving cetuximab and switched to cisplatin were designated as recipients of cetuximab.
The primary outcome in this study was OS. Secondary outcomes included the incidence of major treatment toxicities as recorded with diagnostic coding in the CDW data files. Survival times for primary analyses were calculated from the date of first systemic therapy administration to the date of death or censoring on March 1, 2017. Time-to-event analyses of drug toxicities were calculated with the time from the initiation of either cetuximab or cisplatin to the earliest date of the event of interest, death, or the end of the event window (60 days for acute events and the last date of Veterans Health Affairs health care contact for chronic events). The study was approved by the institutional review board of the James J. Peters VA Medical Center.
Statistical Analysis
We tested for differences in baseline and clinical characteristics between cisplatin and cetuximab treatment groups with the chi-square test for categorical variables and with the t test or Wilcoxon test for normal or nonnormal continuous variables, respectively. In unmatched analyses, we compared OS by fitting Cox regression models, first for all anatomic sites and then with stratification by anatomic site groups. Because of expected differences in the characteristics of the patients receiving treatment with cisplatin or cetuximab (eg, renal function, age, and comorbidity), we used propensity score (PS) analysis to minimize the allocation bias associated with the use of different therapies 24 ; this has been successfully used to analyze the outcomes of different cancer interventions. 20, 25 We calculated PS for the study cohort by determining the probability of the use of cetuximab with logistic regression. Variables included in the PS were as follows: sociodemographic characteristics (age, race, sex, and marital status), smoking and alcohol use, comorbidity score-estimated glomerular filtration rate, baseline neuropathy and hearing loss, tumor characteristics (overall stage, T stage, and N stage), year of diagnosis, and annual HNSCC treatment volume at the treating VA medical center. Variable types were included in the PS model as shown in Table 1 , except for HNSCC treatment volume which was categorized by quartiles. Smoking status, T stage, N stage, and alcohol use all had missing values (3%, 0.7%, %, 0.04%, and 6.1%, respectively); we used multiple imputation methods to estimate missing values for the PS calculation. PS distributions were appropriate for a comparison of treatments (box plots; Supporting Fig. 1) . A PS-matched cohort was then created: cetuximab-treated patients were matched to up to 3 cisplatin-treated patients, and this yielded a cohort of 2361 subjects (1569 cisplatin and 792 cetuximab) with a PS caliper of 0.04. 26 We fitted Cox regression models comparing primary outcomes (survival and toxicity outcomes) between treatment groups in the matched cohort with robust standard errors.
In a secondary analysis, we also compared outcomes according to the cisplatin dose. Although prior data have shown no differences in outcomes between HDC and LDC, 18 many clinicians consider LDC or cetuximab for patients ineligible for HDC. For this analysis, we created additional PS-matched cohorts: 792 cetuximab patients were matched to up to 1 LDC comparator (with a PS caliper of 0.05) to yield a matched cohort of 1108, and 792 cetuximab patients were matched to up to 2 HDC comparators (with a PS caliper of 0.05) to yield a matched cohort of 2029. We then fit logistic regression models for toxicities between treatment groups in the matched cohorts (the overall cisplatin-and LDC-matched cohorts described previously) with robust standard errors. All analyses were performed with SAS 9.2 and Stata 15.
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RESULTS
Patient Characteristics
See Figure 1 for a Consolidated Standards of Reporting Trials diagram of how we arrived at our analytic sample of 4520 patients with stage III to IVb HNSCC. Patients receiving cisplatin were younger (Table 1 ; P < .001) and were more likely to be white (P < .001) and current smokers (P < .001). Patients receiving cisplatin had a different distribution of primary sites, with a higher percentage of laryngeal/hypopharyngeal cancers (P = .035). There was no difference between treatment groups in terms of the T or N stage. Cisplatin-treated patients had a higher baseline glomerular filtration rate (P < .001), a lower prevalence of baseline hearing loss (P < .001), and less neuropathy (P < .001). Patients receiving cisplatin had a lower comorbidity score (P < .001). The use of cetuximab increased over time (P < .001). The median cumulative dose of cisplatin was 164 mg/m 2 (120 mg/m 2 among patients receiving LDC and 180 mg/m 2 among patients receiving HDC). Cumulative dosing information was not available for cetuximab, so a comparison of dose intensities was not performed. 
Survival Outcomes
In an unmatched survival analysis of all HNSCC cases, cetuximab treatment was associated with lower OS in comparison with cisplatin (hazard ratio [HR] for death, 1.70; 95% confidence interval [CI] 1.56-1.86; P < .001). The median OS was 3.8 years for cisplatin and 1.5 years for cetuximab (see Fig. 2A-D) . Cetuximab was associated with lower survival for patients with tumors arising in all primary sites. After PS matching, cetuximab continued to be associated with inferior OS in the full cohort (HR, 1.61; 95% CI, 1.44-1.79; P < .001) and in all primary sites ( Table 2 and Fig. 3A-D) . The median OS in the PSmatched cohort was 4.1 years for cisplatin and 1.7 years for cetuximab. As described previously, we generated separate PS-matched cohorts to evaluate the relative efficacy of cetuximab versus LDC and HDC. Cetuximab was associated with lower survival than LDC (HR, 1.54; 95% CI, 1.34-1.77; P < .001) and HDC (HR, 1.68; 95% CI, 1.49-1.89; P < .001) in these cohorts (Table 2 and Fig. 4A,B) .
Toxicity Outcomes
In a PS-matched analysis of all HNSCC cases, cetuximab was associated with less renal failure, nausea, diarrhea, and hearing loss. Conversely, cetuximab was associated with a higher incidence of rash and mucositis. Neutropenia was not seen with cetuximab, so a statistical comparison was not performed for this adverse event. When we compared cetuximab with LDC in a PSmatched analysis, cetuximab was associated with lower rates of renal failure, percutaneous gastrostomy tube placement, nausea, and hearing loss but a higher rate of rash (see Table 3 ). 
DISCUSSION
In a large cohort of patients with HNSCC, we found that cetuximab given concurrently with RT was associated with lower OS than cisplatin, even after we had accounted for a potential allocation bias in the use of these therapies. These disparities persisted for all tumor primary site subgroups and cisplatin dosing levels. Cisplatin was associated with more toxicity in general than cetuximab, but the disparity was lessened with the use of LDC. Cisplatin and cetuximab are the only Food and Drug Administration-approved systemic therapies for concurrent use with RT for the treatment of HNSCC. Magrini et al 12 randomized patients with locally advanced HNSCC to RT with either cetuximab or LDC. Although the goal was to randomize 130 patients, the study closed early because of slow accrual. Patients receiving cetuximab experienced more cutaneous toxicity but less hematologic and renal toxicity. There were more treatment-related serious adverse events with cetuximab treatment, including 4 deaths. They saw no difference in OS or locoregional control between cetuximab and cisplatin, although the comparison was markedly underpowered; therefore, no definitive conclusions could be drawn regarding the relative efficacy of these common treatment strategies. More recently, a press release describing the results of RTOG 1016 was reported. This study randomized patients with HPV-associated HNSCC to RT with either cisplatin (a limited administration schedule of HDC: 2 doses of 100 mg/m 2 ) or cetuximab. In the press release, cetuximab was noted to be inferior to cisplatin in terms of OS. In our large registry-based analysis, which included patients with HPV-related and HPV-unrelated tumors, we also found worse survival outcomes associated with cetuximab use. In the only other registry-based study to date, which was recently presented at the American Society of Clinical Oncology, Zandberg et al 27 used Surveillance, Epidemiology, and End Results-Medicare data to compare outcomes for patients receiving cetuximab-based bioradiotherapy and patients receiving non-cetuximab regimens and RT monotherapy. 27 Although the results from their analysis showed that cetuximab was associated with inferior outcomes in comparison with other RTsensitizing regimens, the authors did not use a PS analysis to account for bias by allocation. Given the limitations of the Surveillance, Epidemiology, and End Results program, the investigators were unable to comment on chemotherapy dosing.
Our study showed that the toxicity profiles of cisplatin and cetuximab were distinct. As expected, cisplatin was associated with higher rates of renal failure, nausea, and hearing loss. We were surprised to find that cetuximab was associated with a higher rate of mucositis than cisplatin. This is an important finding; the original study by Bonner et al 3 reported that cetuximab was not associated with a higher rate of mucositis than RT alone, whereas cisplatin is known to lead to severe mucositis when it is combined with RT. 10, 11 Despite subsequent studies reporting severe mucositis with cetuximab-based bioradiotherapy, 12, 28 the idea that cetuximab is not associated with mucositis has persisted.
Our comparison of cetuximab with LDC also demonstrated marked inferiority for survival. Current National Comprehensive Cancer Network guidelines recommend the consideration of LDC or cetuximab for patients ineligible for HDC, 29 but scant data differentiate between the therapies; only the underpowered trial previously described prospectively addressed this question. 12 The findings of our study-improved OS with LDC versus cetuximab and similar toxicity profiles for the 2 agents-may support LDC as a preferred treatment approach when comorbid disease is an important clinical consideration.
Our study has several strengths and limitations. First, the CDW does not provide complete RT dosing data. We feel that RT administration is unlikely to vary on the basis of the type of systemic agent. In studies of bioradiotherapy and chemoradiotherapy for locally advanced HNSCC, adherence to the RT dose is generally very high. 3, 10, 11 There was no difference in RT adherence between groups in the study by Magrini et al. 12 Second, we do not know the HPV status for patients with oropharyngeal cancers. Although this is a potentially important limitation, the prognostic impact of HPV is less pronounced among current or former smokers, 30 who make up a substantial portion (90%) of our study population. Our group is currently using various informatics strategies to attempt to determine the HPV status for future analyses. In this study, we saw inferior outcomes across both HPV-related and -unrelated primary sites. Third, the patients receiving cetuximab were older and had greater comorbidity in comparison with the patients receiving cisplatin. Although we controlled for differences in baseline characteristics with the use of PS matching, as with any observational study, there is always the risk of unmeasured confounding. We are reassured by the extensive list of variables available to us in the CDW as well as the appropriate PS correction seen in the box plots (Supporting Fig. 1A-D) . Notably, an unmeasured confounder would need to be strongly associated with both treatment and death to have biased a clinically meaningful association between cetuximab or cisplatin and the results that we observed. Finally, CDW data include clinical information only on veterans. The generalizability of our findings may be limited by the fact that veterans are more likely to be male and have more comorbid illnesses than the general population, 31 which may yield generally inferior cancer-related outcomes. We are not aware of any data indicating that sex is predictive of a response (or lack thereof) to cisplatin or cetuximab.
In summary, our registry-based study shows that cetuximab yields inferior OS in comparison with cisplatin for the nonoperative management of locally advanced HNSCC of the oral cavity, oropharynx, hypopharynx, and larynx. This was seen in both unmatched and PSmatched analyses. Cetuximab was also inferior to both LDC and HDC in a PS-matched analysis. As such, cisplatin may be the preferred systemic therapy concurrent with RT for locally advanced HNSCC.
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